Melanoma, Parkinson's disease and levodopa: Causal or spurious link? A review of the literature

Melanoma Research

Volumn 16, Issue 3, 2006, Pages 201-206

  Zanetti, Roberto ^a   Loria, Dora ^b   Rosso, Stefano ^a  

^a Piedmont Cancer Registry   (Italy)

^b Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Causality; Levodopa; Melanoma; Parkinson's disease; Smoking

Indexed keywords

BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ANAMNESIS; AUTOMATION; BIBLIOGRAPHIC DATABASE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG FATALITY; HEREDITY; HUMAN; HYPOTHESIS; INFORMATION RETRIEVAL; MEDICAL LITERATURE; MELANOMA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SKIN PROTECTION; SMOKING; SOCIAL ASPECT; SOCIAL CLASS;

ANIMALS; HUMANS; LEVODOPA; MELANOMA; MICE; PARKINSON DISEASE; SKIN NEOPLASMS;

EID: 33746150380     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000215043.61306.d7     Document Type: Review

References (61)

1. Skibba JL, Pinckley J, Gilbert EF, Johnson RO. Multiple primary melanoma following administration of levodopa. Arch Pathol Lab Med 1972; 93:556-561.
2. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005; 92:201-205.
3. Lieberman AN, Shupack JL. Levodopa and melanoma. Neurology 1974; 24:340-343.
4. Fermaglich J, Delaney MP. Melanoma and Parkinson's disease. Neurology 1978; 28:404.
5. Sober AJ, Wick MM. Levodopa therapy and malignant melanoma. JAMA 1978; 240:554-555.
6. Botteri A, Nordström PO. Samband mellan levodopa-behandling och maligna tumörer. (Connection between levodopa therapy and malignant tumors) [in Swedish]. Läkartidningen 1979; 76:316-317.
7. Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL. Levodopa administration and multiple primary cutaneous melanomas. Arch Dermatol 1980; 116:1041-1044.
8. Rosin MA, Braun M III. Malignant melanoma and levodopa. Cutis 1984; 33:572-574.
9. Kochar AS. Development of malignant melanoma after levodopa therapy for disease. Report of a case and review of the literature. Am J Med 1985; 79:119-121.
10. Przybilla B, Schwab U, Landthaler M, Braun-Falco O. Development of two malignant melanomas during administration of levodopa. Acta Dermatol Venereol 1985; 65:556-557.
11. Rampen FH. Levodopa and melanoma: three cases and review of literature. J Neurol Neurosurg Psychiatry 1985; 48:585-588.
12. Sandyk R. Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland [letter]. Int J Neurosci 1992; 63:137-140.
13. Haider SA, Thaller VT. Lid melanoma and parkinsonism. Br J Ophthalmol 1992; 76:246-247.
14. Merello M, Esteguy M, Perazzo F, Leiguarda R. Impaired levodopa response in Parkinson's disease during melanoma therapy. Clin Neuropharmacol 1992; 15:69-74.
15. Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN. Levodopa, melanoma, and Parkinson's disease. Neurology 1993; 43:674-677.
16. Woofter MJ, Manyam BV. Safety of long-term levodopa therapy in malignant melanoma. Clin Neuropharmacol 1994; 17:315-319.
17. Kleinhans M, Schmid-Grendelmeier P, Burg G. Levodopa and malignant melanoma: case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma. Hautarzt 1996; 47:432-437.
18. Pfützner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 1997; 37(2 Pt 2):332-336.
19. Wobbes T, Bonenkamp JJ. Melanoma while using levodopa due to Parkinson's disease: causal association unlikely. Ned Tijdschr Geneeskd 2002; 146:1286-1288.
20. Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000; 34:382-385.
21. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al., editors. SEER Cancer Statistics Review, 1973-1999, National Cancer Institute. 2002; Bethesda, Maryland, http://seer.cancer.gov/csr/1973_1999/.
22. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors Cancer incidence in five continents. Vol VIII. Lyon: IARC Scientific Publications; 2003; No 155, IARC.
23. Lew RA, Sober AJ, Cook N, Marvell R, Fitzpatrick TB. Sun exposure habits in patients with cutaneous melanoma: a case control study. J Dermatol Surg Oncol 1983; 9:981-986.
24. Elwood JM, Whitehead SM, Davison J, Stewart M, Galt M. Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour and sunburn. Int J Epidemiol 1990; 19:801-810.
25. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987; 17:459-468.
26. Dubin N, Moeseson M, Pasternack BS. Sun exposure and malignant melanoma among susceptible individuals. Environ Health Perspect 1989; 81:139-151.
27. Loria D, Matos E. Risk factors for cutaneous melanoma: a case control study in Argentina. Int J Dermatol 2001; 40:108-114.
28. Green A, Siskind V, Bain C, Alexander J. Sunburn and malignant melanoma. Br J Cancer 1985; 51:393-397.
29. Holman CDJ, Armstrong BK, Heenan PJ. Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst 1986; 76:403-414.
30. MacKie RM, Aitchison T. Severe sunburn and subsequent risk of primary cutaneous malignant melanoma in Scotland. Br J Cancer 1982; 46:955-960.
31. Tucker MA, Stone BJ, Jensen OM. The Danish case control study of cutaneous malignant melanoma II. Importance of UV-light exposure. Int J Cancer 1988; 42:319-324.
32. Zanetti R, Rosso S, Faggiano F, Roffino R, Colonna S, Martina G. A case control study of melanoma of the skin in the province of Torino, Italy. Rev Epidémiol Santé Publique 1988; 36:309-317.
33. Elwood JM, Whitehead SM, Davison J, Stewart M, Galt M. Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour and sunburn. Int J Epidemiol 1990; 19:801-810.
34. Kessler II. Parkinson's disease in epidemiologic perspective. In: Schoenberg BS, editor. Neurological epidemiology: principles and applications. New York: Raven Press; 1978. pp. 355-383.
35. Duvoisin RC, Eldridge R, Williams A. A twin study of Parkinson's disease. Neurology 1979; 29:578.
36. Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the aetiology of Parkinson's disease: a case control study. Clin Neurol Neurosurg 1976; 79:45-46.
37. Stern M, Dulaney E, Gruber SB, Golbe L, Bergen M, Hurtig H, et al. The epidemiology of Parkinson's disease: a case control study of young-onset and old-onset patients. Arch Neurol 1991; 48:903-907.
38. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33:815-824.
39. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB, et al. Parkinson's disease in twins. Adv Neurol 1984; 40:341-344.
40. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or aetiologic clue? Neurology 1995; 45:1041-1051.
41. Tanner CM, Ben-Shlomo Y. Epidemiology of Parkinson's disease. Adv Neurol 1999; 80:153-159.
42. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 2003; 9:321-327.
43. Kahn HA. The Dorn study of smoking and mortality among US veterans: a report on eight and one-half years of observation. Epidemiological approaches to the study of cancer and other chronic diseases. Natl Cancer Inst Monogr (Washington GPO) 1966; 19:100-125.
44. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. BMJ 1976; 2:1525-1536.
45. Hammond EC. Smoking in relation to the death rates of one million men and women. Epidemiological approaches to the study of cancer and other chronic diseases. Natl Cancer Inst Monogr (Washington GPO) 1966; 19:127-204.
46. Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson's disease. Am J Epidemiol 1968; 88:149-158.
47. Kessler II, Diamond EL. Epidemiologic studies of Parkinson's disease. Smoking and Parkinson's disease: a survey and explanatory hypothesis. Am J Epidemiol 1991; 94:16-25.
48. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999; 52:115-119.
49. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155:732-738.
50. Hirsch EC. Biochemistry of Parkinson's disease with special reference to dopaminergic systems. Mol Neurobiol 1994; 9:135-142.
51. Hearing V. Biochemical control of melanogenesis and melanosomal organization. J Invest Dermatol Symp Proc 1999; 4:24-28.
52. Prota G. Melanins and melanogenesis. San Diego: Academic Press; 1992.
53. Wick MM, Byers L, Frei E III. L-dopa: selective toxicity for melanoma cells in vitro. Science 1977; 197:468-469.
54. Kable EP, Favier D, Parson PG. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine. Cancer Res 1989; 49:2327-2331.
55. Clement MV, Long LH, Ramalingam J, Halliwell B. The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 2002; 81:414-421.
56. Shohat B, Kott E, Bornstein B. The effect of L-dopa, noradrenaline and adrenaline on P-388 mouse leukaemia, B-16 mouse melanoma and E0771 mammary carcinoma. Experimentia 1975; 31:110-111.
57. Maat B. Pigment hyperplasia of epidermis following feeding of L-dopa to elderly rats. J Natl Cancer Inst 1977; 58:1433-1436.
58. Wick MM. An experimental approach to the chemotherapy of melanoma. J Invest Dermatol 1980; 74:63-65.
59. Gurney H, Coates A, Kefford R. The use of L-dopa and carbidopa in metastatic malignant melanoma. J Invest Dermatol 1991; 96:85-87.
60. Sober AJ, Wick MM. Levodopa and melanoma. JAMA 1979; 241:883.
61. Rampen F. Melanoma and levodopa. J Am Acad Dermatol 1998; 38(5 Pt 1):782-784.